FDA Warns Alar Over Ads for Its Unapproved Ketamine Drug

FDA's Office of Prescription Drug Promotion sent Alar Pharmaceuticals an untitled letter, dated 28 August 2026, over promotional materials the company displayed at the American Psychiatric Association's annual meeting in May: an exhibit booth and an accompanying brochure for ALA-3000, an investigational ketamine-based drug for treatment-resistant depression that FDA has not approved for any use. The letter is a reminder of a line regulators draw consistently and enforce just as consistently at medical conferences — a sponsor can talk about a drug still in development, but not in terms that read like a marketing claim for one already on the market.

What the materials claimed

ALA-3000 is still in early clinical development; Alar reported Phase 1 results for the drug earlier in 2026 under a promotional banner — “Alar Breaks Key Barriers in Ketamine Therapy” — touting a long-acting, extended-release profile as a potential improvement on existing ketamine-based treatment for treatment-resistant depression. According to FDA's letter, that same framing carried over into the exhibit booth display and brochure the company showed clinicians at the APA meeting: claims that the drug's sustained-release design avoids the pronounced initial-dose effects associated with other ketamine products, and that it does not carry the sedation, dissociation, or psychosis-like effects seen with ketamine generally. FDA's objection is not to the underlying research — it is to presenting Phase 1 findings on an unapproved drug in the register of a settled, comparative marketing claim, before the safety and efficacy record exists to back it.

Why pre-approval promotion draws this letter, specifically

FDA's promotional rules apply differently to a drug that hasn't been approved. A sponsor may discuss an investigational product's clinical trial design and scientific rationale in appropriate scientific-exchange settings, but it may not promote it — and a conference exhibit booth with a branded display and a take-home brochure sits squarely in promotional territory, not scientific exchange, regardless of the audience being physicians rather than consumers. FDA's letter frames the core problem as claims made in a promotional context about safety and efficacy for a product with no FDA-reviewed data to support them, compounded here by ketamine's own known risk profile: sedation, dissociation, respiratory depression, hemodynamic instability, and abuse potential are all established concerns for the drug class, which sharpens the agency's concern when a sponsor's own materials suggest those risks have been engineered away before the trials that would demonstrate it are complete.

What an untitled letter does and doesn't do

• Not a warning letter: an untitled letter cites promotional violations that FDA has not determined rise to the more serious category requiring a warning letter, and does not itself state a compliance deadline.
• A demand to stop: the recipient is expected to cease use of the violative materials and to respond to FDA describing how it will do so.
• No civil or criminal penalty attached directly: the consequence is reputational and regulatory-relationship risk, plus the record it creates if similar conduct recurs.
• Status as of publication: Regulatory News found no indication that FDA has taken further action against Alar beyond the letter itself.